Award
National Institute of Allergy and Infectious Diseases 5R01AI174540-03
A role for pharmaceutical control of protease-activated receptor-2 for the treatment of asthma
Recipient
University of Arizona, Tucson, AZ, United States
Award Amount
$761,371.00
Ceiling
$761,371.00
Awarded
June 01, 2026
Identifier
5R01AI174540-03
NIH funded project to develop novel PAR2 antagonists for asthma therapy, involving in vitro and in vivo studies and potential clinical trials.
Description
This project aims to develop small molecule antagonists to PAR2 to inhibit allergen-induced asthma symptoms, using in vitro and in vivo models, with plans for human validation. It focuses on asthma treatment via pharmacological control of PAR2, involving mechanistic studies and potential clinical applications.